查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447728

慢性蕁麻疹市場評估：按治療、診斷、給藥途徑、最終用戶和地區劃分的機會和預測（2017-2031）

Chronic Spontaneous Urticaria Market Assessment, By Treatment, By Diagnosis, By Route of Administration, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5個工作天內

價格

全球慢性蕁麻疹市場規模將從2023年的20.1億美元增長到2031年的49.5億美元，2024-2031年預測期間複合年增長率為11.93%。預計將增長至。

多種因素正在推動全球已形成慢性蕁麻疹市場。 由於突破性的發現和對該疾病的了解的加深，慢性蕁麻疹的全球市場正在顯著擴大。

徹底闡明蕁麻疹的基本機制有助於開發更強大的治療藥物。 隨著製藥公司和醫療保健提供者增加研發資金，新的治療方法也不斷被發現並推向市場。 隨著對慢性蕁麻疹病理生理學的了解不斷深入，人們開發出更有效、更有針對性的藥物，與傳統方法相比，這些藥物可以更好地緩解症狀。 全球慢性蕁麻疹市場也受到皮下給藥的影響。 這種方法非常有效，因為它可以讓藥物完全吸收，而不會影響患者的末梢系統，也不存在損傷血管或神經的可能性。

2023 年 8 月，諾華報告了 III 期 REMIX-1 和 REMIX-2 研究的陽性頂線數據，該研究評估了 BTK 抑制劑瑞布替尼 25 mg b.i.d. 對慢性蕁麻疹患者的療效。 如果獲得批准，瑞米布替尼可能成為十年來第一個治療慢性蕁麻疹的藥物，為60% 對H1 抗組織胺沒有反應的患者提供一種簡單而有效的替代方案。

大力投資促進研發

全球慢性蕁麻疹市場的成長也得益於製藥公司對研發活動的持續關注。 市場主要參與者正在投資數十億美元的研究工作，以尋找治療慢性蕁麻疹患者的創新解決方案。 透過研究，公司可以深入了解這種疾病治療的相關因素。

大量投資改善醫療基礎建設

鑑於對高效慢性蕁麻疹治療的需求不斷增長，全球慢性蕁麻疹市場的主要參與者正在加緊努力透過投資改善醫療基礎設施。 這種經過深思熟慮的行動是由於慢性蕁麻疹發生率上升而引發的。 慢性蕁麻疹是一種以無明顯原因突然發作的腫脹和蕁麻疹為特徵的疾病。 透過向醫療基礎設施投入更多資金，這些公司希望創造和提供新的、更強大的治療方法。 除了表現出致力於滿足慢性蕁麻疹患者未滿足的需求之外，這項投資還將顯著推動市場發展，因為更好的治療方法會帶來更好的患者結果，並增加對尖端治療方法的需求。這表明這是可能的。

本報告調查了全球慢性蕁麻疹市場，提供市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素。我們編制分析、案例研究、競爭格局、主要公司簡介等等。

目錄

第1章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第4章全球慢性蕁麻疹市場展望

  • 市場規模/預測
  • 透過治療
    • 藥物
    • 血漿置換
    • 光療
    • 其他
  • 透過診斷
    • 驗血
    • 過敏測試
    • 身體檢查
    • 其他
  • 依給藥途徑
    • 口頭
    • 本地
    • 注射用
    • 其他
  • 按最終用戶
    • 醫院
    • 專科診所
    • 居家護理
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 南美洲
    • 亞太地區
    • 中東/非洲
  • 各公司的市佔率

第5章全球慢性蕁麻疹市場展望：按地區

  • 北美
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第 6 章市場映射

  • 透過治療
  • 透過診斷
  • 依給藥途徑
  • 按最終用戶
  • 按地區

第7章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 抑制生長的因素（問題/抑制因素）

第 9 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第10章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（主要公司）
  • 專利分析（如果適用）

第11章價格分析

第 12 章案例研究

第13章主要公司展望

  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • AstraZeneca plc

第 14 章策略建議

第15章關於我們公司/免責聲明

Product Code: MX11135

The chronic spontaneous urticaria market is projected to witness a CAGR of 11.93% during the forecast period 2024-2031, growing from USD 2.01 billion in 2023 to USD 4.95 billion in 2031. Various factors are shaping the global chronic spontaneous urticaria market such as the increasing prevalence of chronic spontaneous urticaria, significant investments in research and development, availability of suitable medications for treatment, clinical advantages of subcutaneous drugs, and increasing number of clinical trials. The global chronic spontaneous urticaria market, which is defined by recurring hives and angioedema without known triggers, is expanding significantly due to breakthrough discoveries and a better comprehension of the illness.

The creation of more potent treatments is being fueled by a more thorough investigation of the fundamental mechanisms of CSU. New therapeutic options are being discovered and introduced in the market through increased research and development funding from pharmaceutical companies and healthcare providers. Improved knowledge of the pathophysiology of CSU is leading to more effective tailored medicines that provide better symptom alleviation than conventional approaches. The global chronic spontaneous urticaria market is affected by the ability to administer medications subcutaneously. The method is highly effective as it allows complete absorption of the drug without affecting patient's peripheral system and no chances of injury to the vessels and nerves.

Novartis reported positive top-line data in August 2023 from the Phase III REMIX-1 and REMIX-2 studies assessing the BTK inhibitor remibrutinib 25 mg b.i.d. in patients with chronic spontaneous urticaria (CSU). Remibrutinib, if authorized, could be the first medication in a decade to treat chronic spontaneous urticaria (CSU), providing a straightforward and efficient alternative for 60% of patients for whom H1-antihistamines are ineffective.

Significant Investments for Expediting Research and Development

The growth of global chronic spontaneous urticaria market is being driven by a constant focus on research and development activities by pharmaceutical companies. Major companies in the market are spending huge amounts in conducting research activities to find innovative solutions for treating patients with CSU. Through research, companies can discover various insights into the factors revolving around the treatment of the disease. All these factors indicate that there is a strong association between the research efforts and the increasing growth trajectory of the global chronic spontaneous urticaria market. In January 2024, Enanta Pharmaceuticals, a clinical-stage biotechnology company, provided updates on its research and development programs and the outlook for the year 2024, at the 42nd Annual J.P. Morgan healthcare conference. The company announced its expansion into immunology and discovery programs to treat CSU.

Significant Investments for Improving Healthcare Infrastructure

Noticing the increasing need for efficient CSU therapies, major players in the global chronic spontaneous urticaria market are stepping up their efforts to improve healthcare infrastructure through investments. The calculated action is motivated by the rising incidence of CSU, a disorder marked by swelling and hives that develop suddenly and have no apparent reason. These businesses hope to create and offer novel, more potent treatment alternatives by investing more money in the healthcare infrastructure. In addition to demonstrating their dedication to meet the unmet needs of CSU patients, the investment shows the market has the potential to develop significantly due to better treatments resulting in favorable patient outcomes and a rise in demand for cutting-edge therapies.

Many companies in the global chronic spontaneous urticaria market are increasing their investments in the market. For instance, in April 2023, Evommune, Inc. announced the completion of USD 50 million Series B financing to develop new innovative technologies to treat inflammatory diseases such as CSU. Along with current investors EQT Life Sciences and SymBiosis, new investor Arix Bioscience led the funding.

Availability of Novel Medications for Treatment

The development and accessibility of therapeutic alternatives, such as immunosuppressants, biologic therapies, and antihistamines, are the main factors driving the global chronic spontaneous urticaria market. These medications are highly effective due to which their demand in the market is increasing drastically. Medical research advancements have led to the development of many such medications, with more under clinical trials. Second-line drugs like leukotriene receptor antagonists (like montelukast), oral corticosteroids (like prednisone), H2 blockers (like cimetidine), and biologics (like omalizumab; Xolair) may be prescribed to treat patients with refractory symptoms. In January 2024, Evommune, Inc., a clinical-stage biotechnology company, announced the beginning of its human study for Phase 1, to find out EVO756 in adults with CSU. If the trial turns out to be successful, then EVO756 can be the first oral treatment for several diseases such as CSU and inflammatory itch.

Clinical Advantages of Subcutaneous Drugs

Subcutaneous drugs absorb easily without any side effects. Subcutaneous drugs offer numerous clinical benefits such as patient convenience, reduced cost, fewer side effects, enhanced patient satisfaction, and improved drug absorption. With less frequent doses and consistent medication absorption, it can potentially minimize the need for hospital visits and increase patient compliance by enabling self-administration at home. Subcutaneous drugs are highly effective offering a reliable treatment for CSU. Home administration eliminates the need for expensive hospital visits and decreases the demand for medical personnel, resulting in lower healthcare expenses. Compared to intravenous administration, subcutaneous administration often leads to fewer adverse events, particularly those related to infusions, such as infections and hypersensitivity reactions.

On February 16, 2024, Genentech, a member of Roche Group, announced Xolair for the treatment of anaphylaxis and allergic reactions caused due to food allergies in children and adults. It received approval from the U.S. Food and Drug Administration (FDA) and has been cleared for use of treating CSU.

Asia-Pacific to Grow at the Fastest Rate During the Forecast Period

Several countries in Asia-Pacific are going to observe rapid growth in the global chronic spontaneous urticaria market. Economic growth in countries like China and India is going to play a major role in market expansion along with the countries such as China, Japan, India, Australia, and South Korea. The trend can be attributed to the region's increasing population growth, government initiatives, and improving healthcare infrastructure. People are becoming more aware of the illness and its implications, which increases the demand for effective therapies. Additionally, by giving patients more treatment options, the emergence of new pharmaceutical businesses in the market with a focus on cutting-edge CSU therapy promotes market expansion.

On 16 February 2024, Dupixent, a drug used for the treatment of CSU, jointly developed by Sanofi and Regeneron, was granted permission for manufacturing and marketing by the Ministry of Health, Labour and Welfare (MHLW) in Japan.

Future Market Scenario (2024 - 2031F)

To handle the complexity of CSU, businesses are actively seeking novel solutions. For example, Amalizumab, a monoclonal antibody that targets immunoglobulin E (IgE), was developed and is now authorized for use in CSU.

It is anticipated that the creation of novel diagnostic instruments and methodologies will enhance the precision and promptness of CSU diagnosis, resulting in improved patient outcomes. For instance, blood and skin prick tests can be used to determine the underlying cause of CSU, which enables doctors to adjust treatment regimens accordingly.

Advancement in treatment options like targeted therapies and biologics will lead to the expansion of the global spontaneous urticaria market.

Patients are more likely to receive access to cutting-edge CSU medicines and treatments as global healthcare spending rises.

Key Players Landscape and Outlook

The chronic spontaneous urticaria market is expected to experience significant growth in the coming years, driven by factors such as increasing prevalence of urticaria, rising healthcare spending, and technological advancements in medicine and digital health. The market is highly competitive, with key players including Roche, Novartis, Sanofi, AstraZeneca, and GlaxoSmithKline, and others. The global chronic spontaneous urticaria market is witnessing a significant shift towards strategic partnerships among leading companies in the industry. By working together, these organizations can overcome technical and clinical barriers that would otherwise prevent them from moving forward independently.

A Complete Response Letter (CRL) for the supplementary Biologics Licence Application for Dupixent was made available by the U.S. FDA in October 2023. A medication called Dupixent used to treat CSU, is being developed in collaboration with the American biotechnology company Regeneron and Sanofi.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Chronic Spontaneous Urticaria Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Treatment
    • 4.2.1.Medication
    • 4.2.2.Plasmapheresis
    • 4.2.3.Phototherapy
    • 4.2.4.Others
  • 4.3.By Diagnosis
    • 4.3.1.Blood Test
    • 4.3.2.Allergy Test
    • 4.3.3.Physical Examination
    • 4.3.4.Others
  • 4.4.By Route of Administration
    • 4.4.1.Oral
    • 4.4.2.Topical
    • 4.4.3.Parenteral
    • 4.4.4.Others
  • 4.5.By End-user
    • 4.5.1.Hospitals
    • 4.5.2.Specialty Clinics
    • 4.5.3.Homecare
    • 4.5.4.Others
  • 4.6.By Region
    • 4.6.1.North America
    • 4.6.2.Europe
    • 4.6.3.Asia-Pacific
    • 4.6.4.South America
    • 4.6.5.Middle East and Africa
  • 4.7.By Company Market Share (%), 2023

5.Global Chronic Spontaneous Urticaria Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Treatment
      • 5.1.2.1.Medication
      • 5.1.2.2.Plasmapheresis
      • 5.1.2.3.Phototherapy
      • 5.1.2.4.Others
    • 5.1.3.By Diagnosis
      • 5.1.3.1.Blood Test
      • 5.1.3.2.Allergy Test
      • 5.1.3.3.Physical Examination
      • 5.1.3.4.Others
    • 5.1.4.By Route of Administration
      • 5.1.4.1.Oral
      • 5.1.4.2.Topical
      • 5.1.4.3.Parenteral
      • 5.1.4.4.Others
    • 5.1.5.By End-user
      • 5.1.5.1.Hospitals
      • 5.1.5.2.Specialty Clinics
      • 5.1.5.3.Homecare
      • 5.1.5.4.Others
    • 5.1.6.United States*
      • 5.1.6.1.Market Size & Forecast
      • 5.1.6.1.1.By Value
      • 5.1.6.1.2.By Volume
      • 5.1.6.2.By Treatment
      • 5.1.6.2.1.Medication
      • 5.1.6.2.2.Plasmapheresis
      • 5.1.6.2.3.Phototherapy
      • 5.1.6.2.4.Others
      • 5.1.6.3.By Diagnosis
      • 5.1.6.3.1.Blood Test
      • 5.1.6.3.2.Allergy Test
      • 5.1.6.3.3.Physical Examination
      • 5.1.6.3.4.Others
      • 5.1.6.4.By Route of Administration
      • 5.1.6.4.1.Oral
      • 5.1.6.4.2.Topical
      • 5.1.6.4.3.Parenteral
      • 5.1.6.4.4.Others
      • 5.1.6.5.By End-user
      • 5.1.6.5.1.Hospitals
      • 5.1.6.5.2.Specialty Clinics
      • 5.1.6.5.3.Homecare
      • 5.1.6.5.4.Others
    • 5.1.7.Canada
    • 5.1.8.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Treatment
  • 6.2.By Diagnosis
  • 6.3.By Route of Administration
  • 6.4.By End-user
  • 6.5.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Regulatory Approvals
  • 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.F. Hoffmann-La Roche Ltd.
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Teva Pharmaceutical Industries Ltd.
  • 13.3.Sanofi S.A.
  • 13.4.Pfizer Inc.
  • 13.5.GlaxoSmithKline plc
  • 13.6.Novartis AG
  • 13.7.Bayer AG
  • 13.8.Eli Lilly and Company
  • 13.9.Merck & Co., Inc.
  • 13.10.AstraZeneca plc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 2.Global Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 3.Global Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 4.Global Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 5.Global Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 6.Global Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 7.Global Chronic Spontaneous Urticaria Market Share (%), By Region, 2017-2031F
  • Figure 8.North America Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 9.North America Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 10.North America Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 11.North America Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 12.North America Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 13.North America Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 14.North America Chronic Spontaneous Urticaria Market Share (%), By Country, 2017-2031F
  • Figure 15.United States Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 16.United States Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 17.United States Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 18.United States Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 19.United States Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 20.United States Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 21.Canada Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 22.Canada Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 23.Canada Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 24.Canada Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 25.Canada Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 26.Canada Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 27.Mexico Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 28.Mexico Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 29.Mexico Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 30.Mexico Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 31.Mexico Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32.Mexico Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 34.Europe Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 35.Europe Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 36.Europe Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 37.Europe Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 38.Europe Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 39.Europe Chronic Spontaneous Urticaria Market Share (%), By Country, 2017-2031F
  • Figure 40.Germany Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 41.Germany Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 42.Germany Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 43.Germany Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 44.Germany Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 45.Germany Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 46.France Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 47.France Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 48.France Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 49.France Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 50.France Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 51.France Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 52.Italy Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 53.Italy Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 54.Italy Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 55.Italy Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 56.Italy Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 57.Italy Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 58.United Kingdom Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 59.United Kingdom Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 60.United Kingdom Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 61.United Kingdom Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 62.United Kingdom Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63.United Kingdom Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 64.Russia Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 65.Russia Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 66.Russia Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 67.Russia Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 68.Russia Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 69.Russia Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 70.Netherlands Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 71.Netherlands Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 72.Netherlands Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 73.Netherlands Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 74.Netherlands Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 75.Netherlands Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 76.Spain Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 77.Spain Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 78.Spain Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 79.Spain Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 80.Spain Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 81.Spain Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 82.Turkey Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 83.Turkey Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 84.Turkey Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 85.Turkey Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 86.Turkey Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 87.Turkey Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 88.Poland Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 89.Poland Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 90.Poland Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 91.Poland Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 92.Poland Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 93.Poland Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 94.South America Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 95.South America Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 96.South America Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 97.South America Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 98.South America Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99.South America Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 100.South America Chronic Spontaneous Urticaria Market Share (%), By Country, 2017-2031F
  • Figure 101.Brazil Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 102.Brazil Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 103.Brazil Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 104.Brazil Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 105.Brazil Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 106.Brazil Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 107.Argentina Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 108.Argentina Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 109.Argentina Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 110.Argentina Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 111.Argentina Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 112.Argentina Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 113.Asia-Pacific Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 114.Asia-Pacific Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 115.Asia-Pacific Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 116.Asia-Pacific Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 117.Asia-Pacific Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 118.Asia-Pacific Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 119.Asia-Pacific Chronic Spontaneous Urticaria Market Share (%), By Country, 2017-2031F
  • Figure 120.India Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 121.India Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 122.India Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 123.India Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 124.India Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 125.India Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 126.China Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 127.China Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 128.China Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 129.China Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 130.China Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 131.China Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 132.Japan Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 133.Japan Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 134.Japan Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 135.Japan Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 136.Japan Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 137.Japan Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 138.Australia Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 139.Australia Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 140.Australia Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 141.Australia Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 142.Australia Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 143.Australia Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 144.Vietnam Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 145.Vietnam Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 146.Vietnam Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 147.Vietnam Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 148.Vietnam Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 149.Vietnam Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 150.South Korea Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 151.South Korea Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 152.South Korea Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 153.South Korea Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 154.South Korea Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 155.South Korea Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 156.Indonesia Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 157.Indonesia Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 158.Indonesia Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 159.Indonesia Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 160.Indonesia Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 161.Indonesia Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 162.Philippines Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 163.Philippines Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 164.Philippines Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 165.Philippines Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 166.Philippines Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 167.Philippines Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 168.Middle East & Africa Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 169.Middle East & Africa Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 170.Middle East & Africa Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 171.Middle East & Africa Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 172.Middle East & Africa Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 173.Middle East & Africa Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 174.Middle East & Africa Chronic Spontaneous Urticaria Market Share (%), By Country, 2017-2031F
  • Figure 175.Saudi Arabia Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 176.Saudi Arabia Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 177.Saudi Arabia Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 178.Saudi Arabia Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 179.Saudi Arabia Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 180.Saudi Arabia Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 181.UAE Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 182.UAE Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 183.UAE Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 184.UAE Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 185.UAE Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 186.UAE Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 187.South Africa Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
  • Figure 188.South Africa Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 189.South Africa Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
  • Figure 190.South Africa Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
  • Figure 191.South Africa Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
  • Figure 192.South Africa Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
  • Figure 193.By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194.By Diagnosis Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195.By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023